Meperidine binding in maternal and fetal plasma

Research output: Contribution to journalArticleResearchpeer-review

Abstract

Meperidine protein binding was measured in nine pairs of maternal and fetal plasma samples obtained at delivery. For the maternal samples, percent bound and binding ratio (bound/free, B/F) were 63.3 ± 6.18% (SD) and 1.79 ± 0.45, and for the fetal samples the corresponding values were 51.7 ± 4.53% and 1.09 ± 0.21. In each case the binding was higher in the mother than in the fetus (p < 0.01). Plasma α1-acid glycoprotein (α1-AGP) concentrations were higher (p < 0.01) in maternal than in fetal samples, and there was a correlation between meperidine BIF and plasma α1-AGP concentration for the maternal and fetal samples (r = 0.752, p < 0.01). Binding studies with purified α1-AGP showed that this was a cause-effect relationship. The transplacental binding differential was attributable partially to the maternal fetal difference of plasma α1-AGP concentrations. Meperidine was 17.5 ± 0.35% bound in a 3.5 gm/100 ml solution of human serum albumin; however, there was an inverse correlation (r = -0.798, p < 0.01) between BIF and plasma albumin concentration for the maternal and fetal samples. A relatively large proportion (75%) of the overall variability in B/F was accounted for by plasma α1-AGP and albumin. Plasma binding of this basic drug was not greatly influenced by the perinatal levels of bilirubin and nonesterified fatty acids. The common clinical observation of greater fetal than maternal plasma total meperidine concentrations at delivery is not the result of more extensive protein binding in fetal than in maternal plasma.

Original languageEnglish
Pages (from-to)472-479
Number of pages8
JournalClinical Pharmacology and Therapeutics
Volume29
Issue number4
DOIs
Publication statusPublished - 1 Jan 1981

Cite this

@article{63eb706d3fa042799df6954f9544b2b2,
title = "Meperidine binding in maternal and fetal plasma",
abstract = "Meperidine protein binding was measured in nine pairs of maternal and fetal plasma samples obtained at delivery. For the maternal samples, percent bound and binding ratio (bound/free, B/F) were 63.3 ± 6.18{\%} (SD) and 1.79 ± 0.45, and for the fetal samples the corresponding values were 51.7 ± 4.53{\%} and 1.09 ± 0.21. In each case the binding was higher in the mother than in the fetus (p < 0.01). Plasma α1-acid glycoprotein (α1-AGP) concentrations were higher (p < 0.01) in maternal than in fetal samples, and there was a correlation between meperidine BIF and plasma α1-AGP concentration for the maternal and fetal samples (r = 0.752, p < 0.01). Binding studies with purified α1-AGP showed that this was a cause-effect relationship. The transplacental binding differential was attributable partially to the maternal fetal difference of plasma α1-AGP concentrations. Meperidine was 17.5 ± 0.35{\%} bound in a 3.5 gm/100 ml solution of human serum albumin; however, there was an inverse correlation (r = -0.798, p < 0.01) between BIF and plasma albumin concentration for the maternal and fetal samples. A relatively large proportion (75{\%}) of the overall variability in B/F was accounted for by plasma α1-AGP and albumin. Plasma binding of this basic drug was not greatly influenced by the perinatal levels of bilirubin and nonesterified fatty acids. The common clinical observation of greater fetal than maternal plasma total meperidine concentrations at delivery is not the result of more extensive protein binding in fetal than in maternal plasma.",
author = "Nation, {Roger L.}",
year = "1981",
month = "1",
day = "1",
doi = "10.1038/clpt.1981.65",
language = "English",
volume = "29",
pages = "472--479",
journal = "Clinical Pharmacology and Therapeutics",
issn = "0009-9236",
publisher = "American Society for Clinical Pharmacology and Therapeutics",
number = "4",

}

Meperidine binding in maternal and fetal plasma. / Nation, Roger L.

In: Clinical Pharmacology and Therapeutics, Vol. 29, No. 4, 01.01.1981, p. 472-479.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Meperidine binding in maternal and fetal plasma

AU - Nation, Roger L.

PY - 1981/1/1

Y1 - 1981/1/1

N2 - Meperidine protein binding was measured in nine pairs of maternal and fetal plasma samples obtained at delivery. For the maternal samples, percent bound and binding ratio (bound/free, B/F) were 63.3 ± 6.18% (SD) and 1.79 ± 0.45, and for the fetal samples the corresponding values were 51.7 ± 4.53% and 1.09 ± 0.21. In each case the binding was higher in the mother than in the fetus (p < 0.01). Plasma α1-acid glycoprotein (α1-AGP) concentrations were higher (p < 0.01) in maternal than in fetal samples, and there was a correlation between meperidine BIF and plasma α1-AGP concentration for the maternal and fetal samples (r = 0.752, p < 0.01). Binding studies with purified α1-AGP showed that this was a cause-effect relationship. The transplacental binding differential was attributable partially to the maternal fetal difference of plasma α1-AGP concentrations. Meperidine was 17.5 ± 0.35% bound in a 3.5 gm/100 ml solution of human serum albumin; however, there was an inverse correlation (r = -0.798, p < 0.01) between BIF and plasma albumin concentration for the maternal and fetal samples. A relatively large proportion (75%) of the overall variability in B/F was accounted for by plasma α1-AGP and albumin. Plasma binding of this basic drug was not greatly influenced by the perinatal levels of bilirubin and nonesterified fatty acids. The common clinical observation of greater fetal than maternal plasma total meperidine concentrations at delivery is not the result of more extensive protein binding in fetal than in maternal plasma.

AB - Meperidine protein binding was measured in nine pairs of maternal and fetal plasma samples obtained at delivery. For the maternal samples, percent bound and binding ratio (bound/free, B/F) were 63.3 ± 6.18% (SD) and 1.79 ± 0.45, and for the fetal samples the corresponding values were 51.7 ± 4.53% and 1.09 ± 0.21. In each case the binding was higher in the mother than in the fetus (p < 0.01). Plasma α1-acid glycoprotein (α1-AGP) concentrations were higher (p < 0.01) in maternal than in fetal samples, and there was a correlation between meperidine BIF and plasma α1-AGP concentration for the maternal and fetal samples (r = 0.752, p < 0.01). Binding studies with purified α1-AGP showed that this was a cause-effect relationship. The transplacental binding differential was attributable partially to the maternal fetal difference of plasma α1-AGP concentrations. Meperidine was 17.5 ± 0.35% bound in a 3.5 gm/100 ml solution of human serum albumin; however, there was an inverse correlation (r = -0.798, p < 0.01) between BIF and plasma albumin concentration for the maternal and fetal samples. A relatively large proportion (75%) of the overall variability in B/F was accounted for by plasma α1-AGP and albumin. Plasma binding of this basic drug was not greatly influenced by the perinatal levels of bilirubin and nonesterified fatty acids. The common clinical observation of greater fetal than maternal plasma total meperidine concentrations at delivery is not the result of more extensive protein binding in fetal than in maternal plasma.

UR - http://www.scopus.com/inward/record.url?scp=0019409505&partnerID=8YFLogxK

U2 - 10.1038/clpt.1981.65

DO - 10.1038/clpt.1981.65

M3 - Article

VL - 29

SP - 472

EP - 479

JO - Clinical Pharmacology and Therapeutics

JF - Clinical Pharmacology and Therapeutics

SN - 0009-9236

IS - 4

ER -